-
平臺(tái)編號(hào)：bio-68894
-
國(guó)際編號(hào)：HB-8613?
-
細(xì)胞信息： Lym-2
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
Lym-2
ATCC Number：HB-8613?
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
是否是腫瘤細(xì)胞：0
物種來源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
規(guī)格：0.5mg Designations: Lym-2
Depositors: ?Northwestern University
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against chronic lymphocytic leukemia (CLL) cells
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with CLL cells.
Spleen cells were fused with NS-1 myeloma cells.
The antibody stains a majority of human B cell derived tumors, but does not react with solid tumors.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 3902: Epstein AL. Murine hybridoma Lym-2 and diagnostic antibody produced thereby. US Patent 4,724,212 dated Feb 9 1988
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
是否是腫瘤細(xì)胞：0
物種來源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
規(guī)格：0.5mg Designations: Lym-2
Depositors: ?Northwestern University
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against chronic lymphocytic leukemia (CLL) cells
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with CLL cells.
Spleen cells were fused with NS-1 myeloma cells.
The antibody stains a majority of human B cell derived tumors, but does not react with solid tumors.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 3902: Epstein AL. Murine hybridoma Lym-2 and diagnostic antibody produced thereby. US Patent 4,724,212 dated Feb 9 1988
